Use of cyclophosphamide for treatment of fulminant CIDP in the rehabilitation setting

Hamilton Chen

ABSTRACT

Introduction: We present a patient with fulminant chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) refractory to conventional interventions successfully treated with cyclophosphamide. Case Report: 54-year-old male with history of GBS presented to a tertiary care center with bilateral upper and lower extremity weakness, double vision, decreased sensation with bowel movements and micturation, dysphagia, CHF with hypotension, and dyspnea. On examination he demonstrated generalized weakness, areflexia and diminished sensation in bilateral lower extremities. The patient underwent workup, and his laboratory and electrodiagnostic presentation were consistent with CIDP. After he had no response to conventional immunosuppressive treatment, the decision was made to administer cyclophosphamide. The patient demonstrated progressive improvement in his symptoms within one week. He was transferred to the rehabilitation unit and received two additional dosages of cyclophosphamide. He was discharged at an independent level. Conclusion: CIDP is an autoimmune disease driven by an immune response involving T cell activation. It is estimated that 20% of CIDP patients do not respond to the conventional treatments of prednisone, IVIG, and plasma exchange. Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. Previous cases have shown that pulse cyclophosphamide and high dose cyclophosphamide are effective for treating select patients with refractory CIDP, but has never been reported for treatment in patients with fulminant CIDP. Our patient tolerated the medication with few complications. Cyclophosphamide is an option for treatment for fulminant CIDP when conventional immunosuppressive treatment is not effective in the acute and rehabilitation setting.

Keywords: CIDP, Cyclophosphamide, Rehabilitation, IVIG

**********

Chen H. Use of cyclophosphamide for treatment of fulminant CIDP in the rehabilitation setting. International Journal of Case Reports and Images 2012;3(5):16–20.

**********

doi:10.5348/ijc-2012-05-118-CR-3

INTRODUCTION

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune disease that is driven by an immune response involving T cell activation resulting in segmental demyelination [1, 2]. Due to the autoimmune nature of the illness, clinical trials have demonstrated few effective treatments. Randomized trials have shown the efficacy of prednisone in treatment of CIDP. IVIG has been used...
successfully in four randomized placebo-controlled trials [3–6]. Plasma exchange has also been shown to be effective [7–9]. Often, these studies have shown the treatments to offer only a temporal benefit. In addition, it is estimated that up to 20% of CIDP patients do not respond to the conventional treatments [10].

For the reasons mentioned above, immunosuppressive therapies have long been instituted in small clinical trials and case reports. Good et al. demonstrated that pulse cyclophosphamide administered over a period of six months is effective for treating CIDP [11]. Brannagan et al. demonstrated that high dose cyclophosphamide can also be used to treat patients with chronic CIDP refractory to conventional treatment [12]. We present a patient with fulminant CIDP with symptoms of cardiomyopathy and respiratory failure refractory to conventional measures successfully treated with cyclophosphamide in the hospital setting and subsequently in acute rehabilitation setting.

**CASE REPORT**

A 54-year-old male was transferred from an outside hospital with complaints of bilateral upper and lower extremity weakness. The patient’s symptoms started five months prior to transfer, when he initially had complaints of flu-like symptoms: headache, sinus pain, yellow discharge, and cough. Two weeks after the flu-like symptoms resolved, he began experiencing bilateral lower extremity paresthesias that spread to his bilateral upper extremities. The symptoms of paresthesias evolved into frank numbness, and eventually became associated with motor weakness. The motor weakness started in the lower extremities, and progressed to involve the upper extremities. At this time, the patient presented to an outside hospital, where he was diagnosed with presumed Guillain-Barre syndrome and administered five doses of IVIG. After he was given the medication, the weakness/numbness resolved completely.

The patient was well until four months later, when his bilateral upper extremity and lower extremity paresthesias and numbness recurred. He returned to the outside hospital where he was once again administered IVIG, with minimal relief of symptoms. The patient was then transferred to our facility for further management.

On presentation, the patient was in significant distress. In addition to weakness and paresthesias, he had a myriad of other symptoms: double vision, decreased sensation with bowel movements and micturition, dysphagia, CHF with hypotension, and dyspnea on exertion. On examination, he was alert and oriented. Pupils were reactive 4–2 mm bilaterally; cranial nerves II–XII were intact. Motor exam showed 4/5 strength in biceps, triceps, brachioradialis and hand intrinsics bilaterally. Lower extremity motor exam revealed a generalized 2/5 strength in bilateral hips, knees and dorsiflexion and plantarflexion of ankles. Weakness was slightly worse proximally in each limb. Reflex exam demonstrated areflexia in brachioradialis, biceps, triceps, patella and achilles bilaterally. Sensory exam elicited decreased sensation to light touch in bilateral lower extremities below the L2 level.

Results from lumbar tap are demonstrated in Table 1. The patient had elevated protein in the CSF. Initial nerve conduction studies are shown in Table 2. The patient had greater than 50% prolonged distal motor and sensory latency in median, ulnar and tibial nerves, meeting the electrodiagnostic criteria for EFNS/PNS for typical CIDP [13].

Biopsy of the left sural nerve showed evidence of mild to moderate demyelination on the biopsy. The peroneous longus muscle was also biopsied and demonstrated demyelination and severely atrophied muscle fibers.

The patient’s CIDP symptoms progressed requiring intubation early during hospitalization. Regular clinical examination revealed worsening weakness despite frequent courses of IVIG, prednisone and plasma exchanges. Mechanical ventilation was unable to be weaned off over the course of one month and the patient required a tracheostomy for airway management. A repeat nerve conduction study performed one month after the first nerve conduction study showed worsening of distal motor latency in median, ulnar and tibial nerves, as well as reduced amplitudes and conduction velocity in the median, ulnar, and tibial nerves. Results are shown in Table 3.

With no response to conventional treatment after being symptomatic for over two months, the decision was made to administer cyclophosphamide. The patient was initially treated with cyclophosphamide 1800 mg over 60 minutes and he showed progressive improvement within one week. His initial symptoms of double vision, decreased sensation with bowel movements and micturition, dysphagia and respiratory failure improved. His cardiomyopathy symptoms improved with titration of medication and diuresis. He was successfully weaned off the ventilator and transferred to the acute rehabilitation unit for aggressive physical therapy.

Upon transfer to the rehabilitation unit, patient’s initial evaluation by physical therapy and occupational therapy for ADLs and mobility are shown in Table 4. During his course of rehabilitation, he received two additional dosages of cyclophosphamide of 1800 mg over 60 minutes. After one month of intense physical and occupational therapy, he demonstrated significant improvement in his symptoms and eventually had his

| Lab       | Value | Normal |
|-----------|-------|--------|
| Glucose (mg/dL) | 65    | 50–80  |
| Protein (mg/dL)  | 52    | 15–45  |
| WBC        | 2     | 0–3    |
| RBC        | 3     | 0      |

Table 1: CSF laboratory values.
Table 2: First motor nerve conduction study.

| Site                  | Onset Latency (ms) | Norm Onset Latency (ms) | Amplitude (mV) | Norm Amplitude (mV) | Segments | Distance (cm) | Velocity (m/s) | Norm Velocity (m/s) |
|-----------------------|--------------------|-------------------------|----------------|---------------------|----------|---------------|----------------|------------------|
| R Median-APB          | 7.7                | <4.4                    | 6.0            | >4.9                | Wrist-APB| 7             | 53.1           | >45              |
| Elbow                 | 11.7               |                         | 5.8            |                     | Elbow-Wrist| 21.5         | 40.8           | >49              |
| R Ulnar-ADM           | 4.8                | <4.2                    | 11.5           | >4.9                | Wrist-ADM| 7             | 54.4           | >49              |
| B. Elbow              | 8.8                |                         | 11.3           |                     | B. Elbow-Wrist| 21.5         | 40.8           | >49              |
| A. Elbow              | 11.3               |                         | 11.0           |                     | A. Elbow-B. Elbow| 10           | 40.8           | >49              |
| R Common Peroneal-EDB |                    |                         |                |                     |          |               |                |                  |
| Ankle                 | 12.0               | <6.5                    | 2.9            |                     | Ankle-EDB| 9             |                |                  |
| Fibular Head          | 18.1               |                         | 2.6            |                     | Fib Head-Ankle| 28.5         | 47.1           | >45              |
| Knee                  | 20.1               |                         | 2.6            |                     | Knee-Fib Head| 10           | 48.8           | >45              |
| R Tibial (Knee) AH    |                    |                         |                |                     |          |               |                |                  |
| Ankle                 | 6.4                | <5.8                    | 6.5            |                     | Ankle-AH| 9             |                |                  |
| Knee                  | 15.8               |                         | 6.7            |                     | Knee-Ankle| 39.5         | 42.2           | >41              |

Abbreviations: R – Right; APB – Abductor Pollicis Brevis; ADM – Abductor Digitii Minimi; EDB – Extensor Digitorum Brevis; AH – Abductor Hallucis

tracheostomy decannulated. The patient was discharged home at an independent level.

Cyclophosphamide was relatively well tolerated by our patient. Side effects after administration included: neutropenia, urinary tract infection, and nausea.

**DISCUSSION**

Immunosuppressants have long been used for treatment of refractory CIDP, but randomized controlled trials have only been reported for azathioprine and methotrexate. Azathioprine (2 mg/kg) showed no benefit for treatment of CIDP when added to prednisone in 14 CIDP patients for nine months [14, 15]. No significant benefit was observed when methotrexate 15 mg daily for 24 weeks was compared with placebo in 62 patients treated with IVIG or corticosteroid [16].

Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis, which leads to cell death. It is not active against pluripotent stem cells due to high aldehyde dehydrogenase levels in these cells, but is active against B and T cells. It is a relatively well tolerated chemotherapy drug. Some commonly reported side effects include: alopecia, nausea, headache, lightheadedness, rash, anemia, leukopenia and hemorrhagic cystitis [14]. Previous studies have shown that pulse cyclophosphamide administered over a period of six months is effective for treating refractory CIDP [11]. High dose cyclophosphamide has also been used successfully [12]. However, the treatments in these studies were administered to select population of patients without fulminant symptoms affecting multiple organ systems. Fulminant CIDP symptoms including cardiomyopathy and respiratory failure requiring trachostomy, have, to our knowledge, never been reported to be successfully treated with cyclophosphamide. In addition, cyclophosphamide has never been reported for use in the inpatient acute rehabilitation setting with concurrent physiotherapy.

**CONCLUSION**

As a relatively well tolerated chemotherapy drug, cyclophosphamide can be administered safely for treatment of fulminant CIDP when patients are refractory to conventional immunosuppressive treatment
Table 3: Repeat motor nerve conduction study – one month follow up study.

| Site                  | Onset Latency (ms) | Norm Onset Latency (ms) | Amplitude (mV) | Norm Amplitude (mV) | Segments      | Distance (cm) | Velocity (m/s) | Norm Velocity (m/s) |
|-----------------------|--------------------|-------------------------|----------------|--------------------|---------------|---------------|----------------|-------------------|
| R Median-APB          |                    |                         |                |                    |               |               |                |                   |
| Wrist                 | 10.0               | <4.4                    | 2.1            | >4.9               | Wrist-APB     | 7             | 34.8           | >45               |
| Elbow                 | 15.8               | 1.9                     |                |                    | Elbow-Wrist   | 20            |                |                   |
| L Median-APB          |                    |                         |                |                    |               |               |                |                   |
| Wrist                 | 9.6                | <4.4                    | 3.4            | >4.9               | Wrist-APB     | 7             | 57.1           | >45               |
| Elbow                 | 13.1               | 3.0                     |                |                    | Elbow-Wrist   | 20            |                |                   |
| R Ulnar-ADM           |                    |                         |                |                    |               |               |                |                   |
| Wrist                 | 4.8                | <4.2                    | 11.5           | >4.9               | Wrist-ADM     | 7             | 54.4           | >49               |
| B. Elbow              | 8.8                | 11.3                    |                |                    | B. Elbow -Wrist | 21.5       |                |                   |
| A. Elbow              | 11.3               | 11.0                    |                |                    | A. Elbow-B.Elbow | 10         | 40.8           | >49               |
| L Ulnar-ADM           |                    |                         |                |                    |               |               |                |                   |
| Wrist                 | 6.9                | <4.2                    | 6.8            | >4.9               | Wrist-ADM     | 7             | 44             | >49               |
| B. Elbow              | 11.9               | 6.3                     |                |                    | B. Elbow -Wrist | 22         |                |                   |
| A. Elbow              | 15.0               | 5.9                     |                |                    | A. Elbow-B.Elbow | 10         | 32.8           | >49               |
| R Tibial (Knee) AH    |                    |                         |                |                    |               |               |                |                   |
| Ankle                 | 11.6               | <5.8                    | 2.1            |                    | Ankle-AH      | 9             |                |                   |
| Knee                  | 20.6               | 1.3                     |                |                    | Knee-Ankle    | 38            | 42.2           |                   |
| L Tibial (Knee) AH    |                    |                         |                |                    |               |               |                |                   |
| Ankle                 | 11.3               | <5.8                    | 1.8            |                    | Ankle-AH      | 8             |                |                   |
| Knee                  | 21.6               | 1.4                     |                |                    | Knee-Ankle    | 41            | 40.0           |                   |

Abbreviations: R – Right; APB – Abductor Pollicis Brevis ; ADM – Abductor Digiti Minimi ; EDB – Extensor Digitorum Brevis ; AH – Abductor Hallucis

Table 4: Therapy summary in acute rehabilitation.

|                     | Admission         | Discharge        |
|---------------------|-------------------|------------------|
| Mobility            | Mod/Max Assist    | Independent      |
| Transfers           | Max Assist        | Independent      |
| Gait                | Not Assessed      | Modified         |
| Eating/Grooming     | Supervised        | Independent      |
| Upper Body Dressing | Total Assist      | Independent      |
| Lower Body Dressing | Total Assist      | Independent      |
| Toileting           | Total Assist      | Independent      |
| Bathing             | Total Assist      | Independent      |

with IVIG, prednisone, and plasma exchange. It can be safely used in the subacute and rehabilitation setting with good functional outcomes.

**********

Author Contributions
Hamilton Chen – Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Critical revision of the article, Final approval of the version to be published

Guarantor
The corresponding author is the guarantor of submission.
Conflict of Interest
Authors declare no conflict of interest.

Copyright
© Hamilton Chen 2012; This article is distributed under the terms of Creative Commons attribution 3.0 License which permits unrestricted use, distribution and reproduction in any means provided the original authors and original publisher are properly credited. (Please see www.ijcaserreportsandimages.com/copyright-policy.php for more information.)

REFERENCES
1. Dyck PJ, Laix AC, Ohta M, Bastron JA, Okazaki H, Groover RV. “Chronic Inflammatory Polyradiculoneuropathy.” Mayo Clin Proc 1975;50:621–37.
2. Vallat JM, Sommer C, Magy L. “Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition.” Lancet Neurol 2010 Apr;9(4):402–12.
3. Hahn AF. “Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin.” Neurology 1998;51:816–21.
4. Mendell JR, Barohn RJ, Freimer ML, et al. “Randomized controlled trial of IV Ig in untreated chronic inflammatory demyelinating polyradiculoneuropathy.” Neurology 2001;56:445–9.
5. Thompson N, Choudhary P, Hughes RA, Quinlivan RM. “A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.” J Neurol 1996;243:280–5.
6. Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF. “Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study.” J Neurol Neurosurg Psychiatry 1993.
7. Dyck PJ, Daube J, O'Brien P, et al. “Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy.” N Engl J Med 1986;314:461–5.
8. Hahn AF, Bolton CF, Pillay N, et al. “Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy (CIDP): a double-blind, sham-controlled, cross-over study.” Brain 1996;119:1055–66.
9. Mehdinratta MM, Hughes RAC, Agarwal P. “Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy (Cochrane Review).” Cochrane Database Syst Rev 2004;3:CD003906.
10. Mygland A, Monstad P. “Chronic polynuropathies in Vest-Agder, Norway.” Eur J Neurol 2001;8:157–65.
11. Good JL, Chehrenama M, Mayer RF, Koski CL. “Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy” Neurology 1998;51:1735–3.
12. Brannagan TH, Pradhan A, Heiman-Patterson T, et al. “High-dose cyclophosphamide without stem-cell rescue for refractory CIDP.” Neurology 2002 Jun 25;58(12):1856–8.
13. Dionne A, Nicolle MW, Hahn AF. “Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy.” Muscle Nerve 2010;41:202–7.
14. Koski CL, Humphrey R, Shin ML. “Anti-peripheral myelin antibody in patients with demyelinating neuropathy: quantitative and kinetic determination of serum an antibody by complement component 1 fixation.” Proc Natl Acad Sci USA 1985;82:905–9.
15. Tagawa Y, Yuki N, Hirata K. “Anti-SGPG antibody in CIDP: nosological position of IgM anti-MAG/SGPG antibody-associated neuropathy.” Muscle Nerve 2000;23:895–9.
16. Dyck PJ, O'Brien PC, Oviatt KF, et al. “Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment.” Ann Neurol 1982;11:136–41.